Does Therapy With Anti–TNF-α Improve Glucose Tolerance and Control in Patients With Type 2 Diabetes? | Zendy

Malini Gupta-Ganguli | Zendy; Kyle F. Cox | Zendy; Blake Means | Zendy; Ivan Gerling | Zendy; Solomon S. Solomon | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Does Therapy With Anti–TNF-α Improve Glucose Tolerance and Control in Patients With Type 2 Diabetes?

Author(s) -

Malini Gupta-Ganguli,

Kyle F. Cox,

Blake Means,

Ivan Gerling,

Solomon S. Solomon

Publication year - 2011

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc10-1334

Subject(s) - medicine , diabetes mellitus , type 2 diabetes , impaired glucose tolerance , endocrinology

Type 2 diabetes is associated with insulin resistance (IR). IR is partially caused by the cytokine tumor necrosis factor-α (TNF-α), which is produced in inflammatory fat tissue in muscle, liver, and adipose tissue. Inflamed abdominal fat releases adipokines and inflammatory cytokines, one of which is TNF-α. Past experimental studies using anti–TNF-α therapy in type 2 diabetic patients have been limited in both time and dosage because of the toxicity of these agents.We designed a retrospective study in which anti–TNF-α agents were used in larger therapeutic doses for up to 10 years in patients with rheumatoid arthritis (RA) and Crohn's disease (CR). We assessed the effects of this treatment on control of type 2 diabetes. Eight Veterans Affairs patients with RA or CR and type 2 diabetes and a matched group of control patients with both …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research